12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ameluz regulatory update

The European Commission approved Ameluz from Biofrontera to treat actinic keratosis. Ameluz is a photodynamic...

Read the full 55 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >